Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.

7 Dec 2015

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon Pharmaceuticals, Inc. announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study.

1 Dec 2015

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Impax Laboratories, Inc. today announced that the European Commission has granted marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease.

25 Nov 2015

Women with moderate-to-severe PMS at increased risk of developing high blood pressure in later life

In the first prospective study to consider premenstrual syndrome (PMS) as a possible sentinel for future risk of hypertension, epidemiologist Elizabeth Bertone-Johnson and colleagues in the School of Public Health and Health Sciences at the University of Massachusetts Amherst and the Harvard School of Public Health report that women with moderate-to-severe PMS had a 40 percent higher risk of developing high blood pressure over the following 20 years compared to women experiencing few menstrual symptoms.

25 Nov 2015

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

23 Nov 2015

People who experience persistent heartburn despite over-the-counter treatments need to check with their doctors

If Thanksgiving makes you wince at the thought of impending heartburn pain, you are probably not alone. But if you experience heartburn more than twice a week despite over-the-counter treatments, a Jefferson expert wants you to check with your doctor. Gastroesophageal Reflux Disease (GERD) Awareness Week is observed each year during the week of Thanksgiving, a fitting time as Americans prepare to indulge in the holiday season.

23 Nov 2015

Compared to monotherapy combination of pills for advanced skin cancer extends survival

The combination of cobimetinib and Zelboraf® (vemurafenib) has been shown to extend the lives of previously untreated patients with advanced skin cancer to nearly two years (22.3 months)

23 Nov 2015

Researchers receive $6 million to further develop potential treatment for cocaine abuse

University of Kentucky College of Pharmacy Professor Chang-Guo Zhan, along with fellow UK Professors Fang Zheng and Sharon Walsh, and Professor Mei-Chuan Ko from Wake Forest University, recently received $6 million in funding over five years to further develop a potential treatment for cocaine abuse.

21 Nov 2015

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.

21 Nov 2015

NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

The National Institute for Health and Care Excellence today issued its Final Appraisal Determination (FAD) recommending Xofigo (radium-223 dichloride) for use on the NHS in England as an option for treating adult men, with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy.

20 Nov 2015

Medical researchers use social media to study harmful side effects of narcotics medication

Harnessing the power of social media, medical researchers have sifted through more than two billion tweets and online posts to study the harmful side effects of narcotics medication taken for chronic pain.

19 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

Today the U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Opioids are a class of drugs that include prescription medications such as oxycodone, hydrocodone, and morphine, as well as the illegal drug heroin.

18 Nov 2015

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.

17 Nov 2015

Personalized approach to treating side-effects of chemotherapy better for cancer patients

A new research study led by Dr. Mark Clemons, oncologist and associate cancer research scientist at The Ottawa Hospital, has shown that a personalized approach to treating one of the most expected side-effects of chemotherapy is far more effective than the existing "one size fits all" set of guidelines.

13 Nov 2015

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

10 Nov 2015

European regulator concludes that evidence does not support a causal relationship between human papillomavirus vaccines and CRPS or POTS

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a detailed scientific review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines.

10 Nov 2015

Gastric balloon in a pill helps patients lose weight without surgery or endoscopy

A new gastric balloon that can be swallowed like a pill and then filled while in the stomach, helped patients lose more than 37 percent of their excess weight over four months, according to new research presented here at ObesityWeek 2015, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity. The weeklong conference is hosted by the American Society for Metabolic and Bariatric Surgery (ASMBS) and The Obesity Society (TOS).

10 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

Nausea News and Research

Further Reading

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Women with moderate-to-severe PMS at increased risk of developing high blood pressure in later life

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

People who experience persistent heartburn despite over-the-counter treatments need to check with their doctors

Compared to monotherapy combination of pills for advanced skin cancer extends survival

Researchers receive $6 million to further develop potential treatment for cocaine abuse

Ninlaro (ixazomib) approved to treat people with multiple myeloma

NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

Medical researchers use social media to study harmful side effects of narcotics medication

Lilly, Merck expand oncology clinical trial collaboration

FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Personalized approach to treating side-effects of chemotherapy better for cancer patients

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

European regulator concludes that evidence does not support a causal relationship between human papillomavirus vaccines and CRPS or POTS

Gastric balloon in a pill helps patients lose weight without surgery or endoscopy

AACR rapid and dramatic responses in TRK fusion patients

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News